Latest Regulatory Approvals News

Omnia Metals Group Limited has issued a prospectus to list up to 10,000 options, aiming to remove trading restrictions and facilitate secondary market activity. This move follows recent capital raisings and shareholder approvals, positioning the company for enhanced liquidity.

Cue Energy Resources reported a 10.4% increase in revenue to $54.8 million for FY2025, driven by stable production and higher gas prices, but net profit after tax halved to $6.32 million due to rising costs. The company declared a final dividend of 0.5 cents per share.

BCI Minerals has transitioned to full-scale operations at its Mardie Salt Project, marking a pivotal moment with strong construction progress, secured financing, and binding offtake agreements. The company remains on track for first salt shipment by late 2026.

Arovella Therapeutics reported a 14% reduction in net loss to $7.5 million for FY25, bolstered by a $15 million capital raise to fund its lead iNKT cell therapy program progressing toward a pivotal phase 1 clinical trial.

Cuscal Limited has reported a strong FY25 performance exceeding its Prospectus forecasts and announced a $75 million cash acquisition of Indue Limited, aiming to create a more resilient and competitive payments business.

Brazilian Critical Minerals secures robust support from Amazonas state and local authorities for its Ema Rare Earth Project, advancing environmental permitting with unanimous community approval.

Cuscal Limited has exceeded its FY25 profit expectations and announced a strategic $75 million acquisition of Indue Limited, aiming to boost scale and efficiency in the Australian payments sector.

Cuscal Limited reported a 6% revenue increase for FY25 and announced a strategic acquisition of Indue, alongside a leadership change and a higher final dividend.

Vysarn Limited delivered a robust FY2025 performance, driven by significant acquisitions and expanding operations across Australia’s water infrastructure sector. The company’s strategic moves position it well for sustained growth amid evolving market demands.

Reef Casino Trust reported a 23.9% decline in half-year net profit due to higher regulatory and transaction costs, while announcing a recommended takeover bid at $3.72 per unit. The Trust declared a reduced distribution of 6.63 cents per unit.

Atomo Diagnostics reports a significant expansion in its supply agreement with Lumos for the Pascal test cassette, tied to the promising CLIA waiver status of the FebriDx test in the US. This deal could nearly double Atomo’s revenues over the next three years.

Papyrus Australia clarifies it has signed a binding term sheet, not a final agreement, with AQN for biodegradable boards, contingent on facility setup and product testing.